China Healthcare Weekly (Nov.17) - 2023 NRDL Negotiation, Financing Data Won't Lie, Intco Medical
The 2023 NRDL negotiation has officially begun since Friday. Based on 23Q3 data, financing environment in China and overseas markets is far from...
394 Views
China Healthcare Weekly (Oct.27) - TCM Formula Granules VBP, Medical Statistics to Watch, Livzon
Results of the first TCM formula granule VBP were announced. Some key points of Statistical Bulletin on the Development of Health Care worth...
448 Views
A-H Premium Weekly (Jul 28th): China Vanke, CITIC Sec, China Pacific, BYD, CMOC, GF Sec, CICC
We analyzed A-H premium changes in the past week and highlight A-H premium changes for China Vanke, CITIC Sec, China Pacific, BYD, CMOC, GF Sec, CICC.
323 Views
Smartkarma Originals
China Population Policies Impact on Healthcare Companies Series - Part 1
China's population problem is already very serious. So, the government has begun to take a series of measures to optimize fertility policies. We...
920 Views
China Healthcare Weekly (Jul.7) - New NRDL Negotiation Rules, Assisted Reproduction Payment, Kintor
Investors should not be overly optimistic about the new NRDL negotiation rule of innovative drug. Assisted reproduction technology will be covered...
435 Views